(Q48136909)

9 February 2018

title

Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma (English)

1 reference

9 February 2018

0 references

1 reference

Alexander Leins

1

1 reference

9 February 2018

Pietro Riva

2

1 reference

9 February 2018

Ragnar Lindstedt

3

1 reference

9 February 2018

Michail S Davidoff

4

1 reference

9 February 2018

Parviz Mehraein

5

1 reference

9 February 2018

Serge Weis

6

1 reference

9 February 2018

language of work or name

English

0 references

publication date

1 December 2003

1 reference

9 February 2018

published in

Cancer

1 reference

9 February 2018

volume

98

1 reference

9 February 2018

issue

11

1 reference

9 February 2018

page(s)

2430-2439

1 reference

9 February 2018

Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Tenascin mRNA isoforms in the developing mouse brain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Cell-extracellular matrix interaction in glioma invasion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Tenascin distribution in human brain tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Differential expression of tenascin-C and tenascin-X in human astrocytomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Differentiation and proliferative activity in benign and malignant cartilage tumors of bone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Tenascin-C expression in the cyst wall and fluid of human brain tumors correlates with angiogenesis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Intralesional administration of I-131 labelled monoclonal antibodies in the treatment of malignant gliomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody BC-2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Biodistribution of 111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblastomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

The new WHO classification of brain tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Tenascin expression in human glioma cell lines and normal tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Colocalization of tenascin with versican, a hyaluronate-binding chondroitin sulfate proteoglycan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Expression of adhesion factors and degrading proteins in primary and secondary glioblastomas and their precursor tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Role of extracellular matrix in tumor invasion: migration of glioma cells along fibronectin-positive mesenchymal cell processes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Focal brain injury and upregulation of a developmentally regulated extracellular matrix protein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Enhanced expression of the developmentally regulated extracellular matrix molecule tenascin following adult brain injury

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Clinical impact and functional aspects of tenascin-C expression during glioma progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Substrates for astrocytoma invasion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: Biologic and pathologic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11796

7 January 2021

Identifiers

DOI

10.1002/CNCR.11796

1 reference

9 February 2018

1 reference

9 February 2018